Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057398 | 0.83 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9509419 | 0.80 | CA1 (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23909484 | 0.77 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23909482 | 0.77 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5141071 | 0.77 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23909471 | 0.76 | CTSK (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23909472 | 0.76 | CTSK (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29255570 | 0.75 | CYP1A2 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9512401 | 0.75 | CYP1A2 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3933529 | 0.74 | CYP2C19 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | CTSK 95/4885CTSS 83/4885CA1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.